Short-Term Prognosis Value of sST2 for an Unfavorable Outcome in Hypertensive Patients

Table 1

Baseline characteristics of all patients, group A, and group B.

Characteristics	All patients 80 (%)		Group A (HBP with CV events); 36 patients	Group B (HBP without CV events); 44 patients
Age					0.06
Sex
Men	38 (47.5%)	0.051	18 (50%)	20 (45.45%)	0.061
Women	42 (52.5%)		18 (50%)	24 (54.54%)	0.052
Hypertension (HBP)
Stage I	20 (25%)	<0.001^a	10 (27.77%)	10 (22.72%)	0.028
Stage II	34 (42.5%)	0.002^b	12 (27.77%)	22 (50%)	0.001
Stage III	26 (32.5%)	0.023^c	14 (38.88%)	12 (27.27%)	0.005
Additional cardiovascular risk
Moderate	15 (18.75%)	0.002^a	3 (8.34%)	12 (27.27%)	0.03
High	33 (41.25%)	0.023^b	12 (33.3%)	21 (47.72%)	0.008^b
Very high	21 (26.25%)	<0.001^c		11 (25%)	0.000^c
Controlled hypertension
No	25 (31.25%)		21 (58.33%)	4 (9.09%)	<0.001
Yes	55 (68.75%)	<0.001	15 (41.66%)	40 (90.90%)	<0.001
Dyslipidaemia
Without	8 (10%)		3 (8.33%)	5 (11.36%)	0.04
Hypercholesterolemia	42 (52.5%)		22 (61.11%)	20 (45.45%)	0.002
Mixed	26 (32.5%)		11 (30.55%)	15 (34.09%)	0.05
Hypertriglyceridemia	4 (5%)		—	4 (9.1%)	—
Smoke
No	58 (72.5%)		18 (50%)	40 (90.9%)	0.001
Yes	22 (27.5%)	0.001	18 (50%)	4 (9.1%)	0.001
BMI
Normal weight	32 (40%)	0.04^a	5 (13.88%)	27 (61.63%)	0.003
Overweight	28 (35%)	0.45^b	16 (44.44%)	12 (27.27%)	0.026
Obese	20 (25%)	0.03^c	15 (41.66%)	5 (11.36%)	0.018
Diabetes mellitus (DM)
No	54 (67.5%)		20 (55.55%)	34 (77.27%)	0.021
Yes	26 (32.5%)	0.001	16 (44.44%)	10 (22.72%)	<0.001

^aComparisons between 1 and 2; ^bcomparisons between 2 and 3; ^ccomparisons between 1 and 3.